Changes of autoantibodies and intercellular adhesion molecule-1 in patients with Graves disease after clinical treatment.
Year: 2021
Type: article
Study design: Observational Study
Abstract: OBJECTIVE: To study the changes of autoantibodies and intercellular adhesion molecule-1 (ICAM-1) in patients with Graves disease (GD) after clinical treatment. METHODS: A total of 68 patients with GD admitted to our hospital from August 2018 to August 2019 were selected as the research objects. The thyroid peroxidase antibody (TPOAb), thyroid stimulating antibody (TSAb), and antithyroglobulin antibody (TgAb), ICAM-1, insulin-like growth factor 1 (IGF-1), Interleukin-6 (IL-6), Interleukin 17 (IL-17) before and after treatment were examined. RESULTS: The levels of TSAb, TgAb and TPOAb after treatment were remarkably lower than those before treatment (P<0.001); the levels of ICAM-1, IGF-1, IL-17 and IL-6 after treatment were noticeably lower than those before treatment (P<0.001); the FT3 and FT4 levels of patients after treatment were significantly lower than those before treatment (P<0.001), and the FSH level was significantly higher than that before treatment (P<0.001). CONCLUSION: Clinical treatment can remarkably reduce the levels of autoantibodies, ICAM-1 and IGF-1 in GD patients, improve thyroid function, and relieve inflammation. The detection of the above indicators can provide guidance for the progression and treatment of GD.
Source: PubMed Central
Authors: Jing Zhang, Rongrong Zhang, Zhenhong Zhao
Institution: Shandong First Medical University
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W3173674063